A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The study will compare the relative bioavailability (rate and extent of absorption) of 200
mg/5 mL Azithromycin oral suspension manufactured by TEVA Pharmaceutical Industries Ltd.;
distributed by TEVA Pharmaceuticals USA with that of 200 mg/5 mL ZITHROMAX oral suspension
distributed by Pfizer labs, a division of Pfizer Inc. following a single oral 10 mL dose (400
mg) in healthy adult subjects administered under non-fasting conditions.